Glutamate receptors as a target for Alzheimer’s disease — are clinical results supporting the hope?

  • B. Winblad
  • H. J. Möbius
  • A. Stöffler
Part of the Journal of Neural Transmission. Supplementa book series (NEURAL SUPPL, volume 62)


Several years after the introduction of cholinergic drugs in Alzheimer’s disease therapy, other approaches for symptomatic and also disease-modifying pharmacotherapy are progressing in their development. Among these, the NMD A antagonist memantine represents the most advanced and promising agent, gifted with many years of clinical experience in Germany. This paper provides an overview of both, the novel pharmacological background and recent clinical evidence in dementia. Memantine was recently recommended for central European approval.


Vascular Dementia Neurobiol Aging Severe Impairment Battery Memantine Treatment Memantine Group 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Barnes CA, Danysz W, Parsons CG (1996) Effects of the uncompetitive NMDA receptor antagonist memantine on hippocampal long-term potentiation, short-term exploratory modulation and spatial memory in awake, freely moving rats. Eur J Neurosci 8: 565–571PubMedCrossRefGoogle Scholar
  2. Cacabelos R, Takeda M, Winblad B (1999) The glutamatergic system and neurode-generation in dementia: preventive strategies in Alzheimer’s disease. Int J Geriatr Psychiatry 14(1): 3–47PubMedCrossRefGoogle Scholar
  3. Danysz W, Parsons CG, Mobius HJ, Stoffler A, Quack G (2000) Neuroprotection and symptomatological action of memantine relevant for Alzheimer’s disease ¡ª an unified hypothesis on the mechanism of action. Neurotox Res 2(2–3): 85–98PubMedCrossRefGoogle Scholar
  4. Davies P (1999) Challenging the cholinergic hypothesis in Alzheimer disease [editorial]. JAMA 281(15): 1433–1444PubMedCrossRefGoogle Scholar
  5. Ditzler K (1991) Efficacy and tolerability of memantine in patients with dementia syndrome. A double-blind, placebo controlled trial. Arzneimittelforschung 41: 773–780PubMedGoogle Scholar
  6. Fratiglioni L, De Ronchi D, Agtiero-Torres H (1999) Worldwide prevalence and incidence of dementia. Drugs Ageing 15:365–375CrossRefGoogle Scholar
  7. Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, Ferris S (1997) An inventory to assess activities of daily living for clinical trials in Alzheimer’s disease. Alzheimers Dis Assoc Disord ll[Suppl 2]: 33–39CrossRefGoogle Scholar
  8. Galasko DR, Schmitt FA, Jin S, Saxton J, Bennett D, Sano M, Ferris SH (2000) Detailed assessment of cognition and activities of daily living in moderate to severe Alzheimer’s disease. Neurobiol Aging 21(1S): 168CrossRefGoogle Scholar
  9. Gortelmeyer R, Erbler H (1992) Memantine in the treatment of mild to moderate dementia syndrome. A double-blind placebo-controlled study. Arzneimittelfor-schung/Drug Res 42(7): 904–913Google Scholar
  10. Greenamyre J, Young A (1989) Excitatory amino acids and Alzheimer’s disease. Neurobiol Aging 10: 593–602PubMedCrossRefGoogle Scholar
  11. Jorm AF, Jolley D (1998) The incidence of dementia: a meta-analysis. Neurology 51(3):728–733PubMedCrossRefGoogle Scholar
  12. Kornhuber J, Weller M (1997) Psychotogenicity and N-methyl-D-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy. Biol Psychiatry 41(2): 135–144PubMedCrossRefGoogle Scholar
  13. Lancelot E, Beal MF (1998) Glutamate toxicity in chronic neurodegenerative disease. Prog Brain Res 116: 331–347PubMedCrossRefGoogle Scholar
  14. Launer LJ, Hofman A (2000) Frequency and impact of neurologic diseases in the elderly of Europe: a collaborative study of population-based cohorts. Neurology 54[11 Suppl5]: 1–8Google Scholar
  15. Lobo A, Launer LJ, Fratiglioni L, Andersen K, Di Carlo A, Breteler MM, Copeland JR,Dartigues JF, Jagger C, Martinez-Lage J, Soininen H, Hofman A (2000) Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54[11 Suppl5]: S4–9PubMedGoogle Scholar
  16. Orgogozo JM, Rigaud AS, Stoffler A, Mobius HJ, Forette F (2002) Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke (in press)Google Scholar
  17. Palmer AM, Gershon S (1990) Is the neuronal basis of Alzheimer’s disease cholinergic or glutamergic? FASEB J 4: 2745–2752Google Scholar
  18. Parsons CG, Gruner R, Rozental J, Millar J, Lodge D (1993) Patch clamp studies on the kinetics and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (l-amino-3,5-dimethyladamantan). Neuropharmacology 32(12): 1337–1350PubMedCrossRefGoogle Scholar
  19. Parsons CG, Danysz W, Quack G (1998) Glutamate in CNS disorders as a target for drug development: an update. Drug News Perspect 11(9): 523–569PubMedCrossRefGoogle Scholar
  20. Reisberg B, Windscheif U, Ferris SH, Hingorani VH, Stoffler A, Mobius HJ (2000) Memantine in moderately severe to severe Alzheimer’s disease (AD): results of a placebo-controlled 6-month trial. Neurobiol Aging 21(1S): S275CrossRefGoogle Scholar
  21. Rosen WG, Terry RD, Fuld PA, Katzman R, Peck A (1980) Pathological verification of ischemic score in differentiation of dementias. Ann Neurol 7(5): 486–488PubMedCrossRefGoogle Scholar
  22. Sahin K, Stoffler A, Furtuna P, Rosenwald D, Mobius HJ (2000) Dementia severity and the magnitude of cognitive benefit by memantine treatment. A subgroup analysis of two placebo-controlled clinical trials in vascular dementia. Neurobiol Aging 21 (IS):S168Google Scholar
  23. Saxton J, McGonigle KL, Swihart AA, Boiler F (1993) The Severe Impairment Battery. The University of Pittsburgh of the Commonwealth System of Higher Education (eds) Thames Valley Test Company, Suffolk, pp 1–16Google Scholar
  24. Sclan SG, Reisberg B (1992) Functional assessment staging (FAST) in Alzheimer’s disease: reliability, validity, and ordinality. Int Psychoger 4[Suppl 1]: 55–69CrossRefGoogle Scholar
  25. Szatkowski M, Atwell D (1994) Triggering and execution of neuronal death in brain ischaemia: two phases of glutamate release by different mechanisms. Trends Neurosci 17(9): 359–365PubMedCrossRefGoogle Scholar
  26. van der Kam P, Mol F, Wimmers MFHC (1986) [Assessment scale for geriatric patients] Beordelingsschaal voor Oudere Patienten (BOP). Van Loghum Slaterus, The NetherlandsGoogle Scholar
  27. Wilcock G, Mobius HJ, Stoffler A, on behalf of the MMM 5000 Group (2002) A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM 500). Int Clin Psychopharmacol (in press)Google Scholar
  28. Winblad B, Poritis N (1999) Memantine in severe dementia, results of the M-BEST study (benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psych 14(2): 135–146CrossRefGoogle Scholar
  29. Winblad B, Wimo A, Mobius HJ, Fox JM, Fratiglioni L (1999) Severe dementia: a common condition entailing high costs at individual and societal levels. Int J Geriatr Psychiatry 14(11): 911–914PubMedCrossRefGoogle Scholar
  30. Zajaczkowski W, Quack G, Danysz W (1996) Infusion of (+)-MK-801 and memantine ¡ªContrasting effects on radial maze learning in rats with entorhinal cortex lesion. Eur J Pharmacol 296: 239–246PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 2002

Authors and Affiliations

  • B. Winblad
    • 1
    • 2
  • H. J. Möbius
    • 3
  • A. Stöffler
    • 3
  1. 1.Karolinska Institute and NeurotecStockholmSweden
  2. 2.Division of Geriatric Medicine B84Huddinge University HospitalStockholmSweden
  3. 3.Merz + Co,Frankfurt/MFederal Republic of Germany

Personalised recommendations